Hyloris’ Maxigesic IV receives FDA approval for pain management
Maxigesic IV, which is a combination of 1000mg paracetamol and 300mg ibuprofen solution, is given intravenously to adults for relieving mild to severe pain. It received approval for
Santhera Pharmaceuticals has reported that the China National Medical Products Administration (NMPA) granted priority review for a new drug application (NDA) for vamorolone, for Duchenne muscular dystrophy (DMD).
CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced
The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not
CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are